Dawn Reporter

Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna

Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna

June 18
18:04 2024
Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna

DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight, 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Squamous Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Squamous Cell Carcinoma Pipeline Outlook

 

Key Takeaways from the Squamous Cell Carcinoma Pipeline Report

  • June 2024;- Merck Sharp & Dohme LLC– The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma.
  • June 2024:- University of Florida– This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
  • June 2024:- Incyte Corporation– This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma.
  • June 2024;- M.D. Anderson Cancer Center– Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
  • June 2024:- AHS Cancer Control Alberta– The purpose of this study is to find out what effects the combination of radiation therapy and Avelumab have on you and your cancer. The effectiveness of this treatment as well as what side effects occur will both be studied.
  • June 2024- Dana-Farber Cancer Institute– In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney transplant.
  • DelveInsight’s Squamous Cell Carcinoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Squamous Cell Carcinoma treatment.
  • The leading Squamous Cell Carcinoma Companies such as Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
  • Promising Squamous Cell Carcinoma Therapies such as SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.

 

Stay informed about the cutting-edge advancements in Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in cancer care @ Squamous Cell Carcinoma Clinical Trials Assessment

 

Squamous Cell Carcinoma Emerging Drugs Profile

 

  • NBTXR-3: Nanobiotix

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.

  • mRNA-4157: Moderna Therapeutics

mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.

  • HB-200: Hookipa Pharma

HB-200 is HOOKIPA’s lead oncology candidate engineered with the company’s proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.

  • MCLA-158: Merus

MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.

  • HFB-301001: HiFiBiO

HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with squamous cell carcinoma.

 

Learn more about Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Squamous Cell Carcinoma Research and development projects @ Squamous Cell Carcinoma Unmet Needs

 

Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

 

Squamous Cell Carcinoma Companies and Therapies

  • Sichuan Baili Pharmaceutical Co., Ltd.: SI-B001
  • InflaRx GmbH: IFX-1
  • Merck Sharp & Dohme LLC: MK-3475A
  • ImmunityBio Inc.- Aldoxorubicin HCl
  • Incyte Corporation: INCB099280

 

Scope of the Squamous Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Squamous Cell Carcinoma Companies- Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
  • Squamous Cell Carcinoma Therapies- SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.
  • Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Squamous Cell Carcinoma Pipeline on our website @ Squamous Cell Carcinoma Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Squamous Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Squamous Cell Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NBTXR-3: Nanobiotix
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. HB-200: Hookipa Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. HFB-301001: HiFiBiO
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Squamous Cell Carcinoma Key Companies
  21. Squamous Cell Carcinoma Key Products
  22. Squamous Cell Carcinoma- Unmet Needs
  23. Squamous Cell Carcinoma- Market Drivers and Barriers
  24. Squamous Cell Carcinoma- Future Perspectives and Conclusion
  25. Squamous Cell Carcinoma Analyst Views
  26. Squamous Cell Carcinoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Author

admin

admin